Investors

Investors 2016-12-09T07:33:03+00:00

Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

Video: NDF Research interview on Phase 2a results

In the interview, Kathy Harrison and Associate Professor David Packham, a Principal Investigator in the DMX-200 Phase 2a study and Director of Melbourne Renal Research Group, discusses Dimerix’s Phase 2a trial result of DMX-200 with [...]

Conference Call Recording: DMX-200 Phase 2a Trial Results

A recording of the public DMX-200 Phase 2a trial presentation and Q&A session is available below.   This presentation was held on 13 July 2017. The corresponding presentation is available here.  

Investor Presentation: DMX200 Phase 2a Trial

Investors are invited to join a conference call to be hosted by Kathy Harrison, CEO at 12.00pm (AEST) on Thursday, 13th July 2017. The call will cover today's release of positive Phase 2a clinical trial [...]

Read More

Media Coverage

Video: NDF Research interview on Phase 2a results

In the interview, Kathy Harrison and Associate Professor David Packham, a Principal Investigator in the DMX-200 Phase 2a study and Director of Melbourne Renal Research Group, discusses Dimerix’s Phase 2a trial result of DMX-200 with [...]

NDF Research: An update report on Dimerix

View the update analyst report on their website.

The Australian: “Trial results ‘exciting’ for biotech Dimerix”

Dimerix CEO Kathy Harrison interviewed by The Australian Read the article on their website.

Gold Coast Investment Showcase Presentation

Dimerix CEO Kathy Harrison Presents at the 2017 Gold Coast Investment Showcase

Read More

Stock Quote

View stock price: ASX Stock Price

Email Alert

subscribe to news updates